Oruka Therapeutics Reported ORKA-001 Trial Data
The drug candidate showed high skin clearance response rates in a study of 84 patients with plaque psoriasis.
Updated on Sept. 23, 2026 in Diseases — General
Live Poll
Do you trust pharmaceutical results from early-stage clinical trials as a basis for treatment?
Oruka Therapeutics has released Week 28 data from its EVERLAST-A trial, revealing strong response rates for its ORKA-001 drug. The study followed 84 patients who received the treatment through Week 4.
Why it matters
These results provide insight into the potential efficacy of ORKA-001 for treating skin conditions, even after dosing concluded early in the study period. Continued monitoring of the trial participants helps determine the long-term sustainability of these therapeutic effects.
The EVERLAST-A trial reported an 84.1% IGA 0/1 response rate at Week 28 among 84 enrolled patients. Serious adverse events identified during the period included one tibial fracture and one case of prostate adenocarcinoma.
The players
Oruka Therapeutics
A biotechnology company based in Menlo Park, Calif., that specializes in developing novel therapeutic treatments for chronic skin diseases.
The details
Patients in the trial received 600 mg doses of ORKA-001 at Week 0 and Week 4, with placebo crossover patients starting treatment later at Week 16 and Week 20. Upper respiratory tract infections were recorded in 8% of the patient population between Week 16 and Week 28.
Timeline
Initial patient dosing began at Week 0.
The second dose was administered at Week 4.
Placebo crossover patients began receiving the drug at Week 16.
Trial data was reported at Week 28.
Full 52-week data is expected in December 2026.
The Big Picture
This report marks a progress point in the ongoing development of biologic therapies for dermatological conditions. It follows the data trajectory set by the EVERLAST-A clinical trial program.
The reported response rates indicate potential future treatment options for patients with skin conditions who are not served by current therapies. Patients should consult their healthcare providers to discuss how these emerging clinical developments may eventually influence future care routines.
The takeaway
These clinical findings suggest that a limited dosing regimen may produce significant and lasting skin clearance for patients. Future data readouts will be essential to confirm if these results hold up over the full 52-week study duration.
What happens next
Full 52-week data for the EVERLAST-A trial is anticipated in December 2026, while the 16-week data for the EVERLAST-B trial is expected in the fourth quarter of 2026.
Further reading
For more on evolving research in this field, visit the Diseases — General section.
Live Poll
Do you trust pharmaceutical results from early-stage clinical trials as a basis for treatment?
